B. Hornig et al., EFFECT OF ACE-INHIBITION ON ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC HEART-FAILURE, European heart journal, 19, 1998, pp. 48-53
The endothelium controls vascular smooth muscle tone by secreting rela
xing and contracting factors. There is a constant release of endotheli
um-derived relaxing: factor(s) (EDRF) under basal conditions. In addit
ion, the endothelium can increase the release of EDRF in response to h
umoral stimulation by vasoactive substances such as acetylcholine or b
radykinin. Under physiological conditions the most important stimulus
to the release of EDRF is an increase in blood flow, leading to increa
sed shear stress on endothelial cells. Recent experimental studies hav
e raised the possibility that bradykinin plays an important role in th
e regulation of vascular tone at rest and during flow-stimulated condi
tions. Bradykinin is a very potent vasodilator that exerts its vasodil
atory actions by causing endothelial release of nitric oxide, prostacy
clin and/or endothelium-derived hyperpolarizing factor. Recent studies
in humans have demonstrated that bradykinin contributes to the regula
tion of coronary vascular tone under resting and flow-stimulated condi
tions. This mechanism has been shown to be important in humans in both
peripheral and coronary arteries. Angiotensin-converting enzyme (ACE)
inhibitors not only decrease angiotensin II but also increase bradyki
nin levels, since ACE is identical to kininase II, which degrades brad
ykinin. The beneficial vascular effects of ACE inhibitors may therefor
e be related to increased availability of bradykinin. Indeed, we have
recently shown that ACE inhibition improves flow-dependent, endotheliu
m-mediated vasodilation and that this beneficial effect is bradykinin-
dependent. Our preliminary data also indicate that ACE inhibition impr
oves endothelium-mediated vasodilation in patients with heart failure
and coronary artery disease due to an enhanced availability of nitric
oxide. These findings suggest that the beneficial vascular effects of
ACE inhibition in heart failure may be due in part to improved endothe
lial function.